Spryson America, Inc.

Spryson America, Inc., a foreign-owned, for-profit manufacturer of neurological diagnostic and rehabilitation equipment, operates as a prime contractor selling specialized medical devices and associated maintenance services to federal health agencies on a full-and-open basis, with no set-asides across its federal footprint.

Spryson manufactures and distributes vestibular assessment and neurorehabilitation systems, head-mounted eye-tracking and display systems, rotary chair diagnostic equipment, and virtual reality diagnostic goggles, alongside multi-year maintenance and repair services for these devices. The company's product line centers on the Neurolign NOTC System (a 6-degree-of-freedom motion chair with integrated VR capability), the DX200 head-mounted goggle system with eye-tracking and high-resolution 3D display, rotary chair systems for vestibular testing, and I-Portal clinical eye-tracking devices. Representative prime awards include a $223,882 purchase order from Veterans Integrated Service Network 6 for a NOTC Pro+ Chair with HIPAA-compliant cloud data management (August 2026), a $249,000 purchase order from the National Institutes of Health Office of Logistics and Acquisition Operations for assorted Neurolign diagnostic systems (September 2024), a $96,000 five-year maintenance contract with Veterans Integrated Service Network 22 for NOTC System upkeep (October 2023), and a $76,000 Defense Health Agency maintenance and repair contract for Neuro Kinetics instrumentation through September 2027 (October 2023).

Customer concentration clusters within defense healthcare and Veterans Affairs networks. The Defense Health Agency leads by award count (14 awards, $675 thousand combined potential value) and by dollar value; the National Institutes of Health, VISN 6, the Department of the Navy Bureau of Medicine and Surgery, and VISN 22 form the secondary tier. Eighteen distinct federal agencies have purchased from Spryson across the source data, though the top five agencies represent 61% of combined potential value — a relatively dispersed customer base for the low absolute dollar volume. The company holds no parent vehicles (GWACs, IDIQs, or BPAs) and operates exclusively under purchase orders, indicating transactional, order-by-order positioning rather than blanket-contract incumbency.

Activity has decelerated sharply. The award portfolio peaked at ten awards in 2022, declined to six in 2023, and dropped to one award in 2024 and two in 2025, with only three awards recorded in 2026 through the August source snapshot. Combined potential value across 46 total awards stands at $2.5 million, though obligated dollars ($3.4 million) exceed that figure, reflecting upward modifications to prior purchase orders. Across the portfolio, work classifies primarily under NAICS 334515 (Electromedical and Electrotherapeutic Apparatus Manufacturing) and 334611 (Other Electronic and Precision Equipment Repair and Maintenance), and under PSC 6515 (Medical and Surgical Instruments, Equipment, and Supplies). Four awards with combined potential value of $422 thousand face completion within the next twenty-four months and represent recompete exposure. Spryson operates no subcontracting relationships within the source data — all 46 awards are carried as prime contracts, and the vendor reports no federal contract vehicle seats or blanket-agreement positions.